Payment overview · 2025
General Payments
$715.53
18 reported records · 8 companies
Healthcare provider profile · identity verified
Jonathan D Condit, DO
Allopathic & Osteopathic Physicians|Family Medicine · MUNCIE, IN · NPI 1194803189
Verified facts
What the public records show
CMS Open Payments records show Jonathan D Condit, DO received $715.53 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $386.20 | 54.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.68 | 22.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.90 | 6.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.78 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.33 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.57 | 2.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.22 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $696.68 | 17 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $386.20 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $116.82 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.90 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 140 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
32 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 871 | 247 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 127 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 397 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 389 | 150 |
| Ramipril | Ramipril | 362 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 345 | 128 |
| Tamsulosin Hcl | Tamsulosin Hcl | 322 | 103 |
| Gabapentin | Gabapentin | 296 | 68 |
| Lisinopril | Lisinopril | 266 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 84 |
| Omeprazole | Omeprazole | 260 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 80 |
| Montelukast Sodium | Montelukast Sodium | 233 | 69 |
| Alendronate Sodium | Alendronate Sodium | 224 | 65 |
| Metformin Hcl | Metformin Hcl | 223 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 219 | 58 |
| Carvedilol | Carvedilol | 218 | 66 |
| Allopurinol | Allopurinol | 215 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 49 |
| Metformin Hcl Er | Metformin Hcl | 149 | 46 |
| Furosemide | Furosemide | 141 | 41 |
| Eliquis | Apixaban | 140 | 43 |
| Potassium Chloride | Potassium Chloride | 134 | 41 |
| Ozempic | Semaglutide | 132 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 129 | 44 |
| Mirtazapine | Mirtazapine | 129 | 37 |
| Farxiga | Dapagliflozin Propanediol | 128 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 39 |
| Losartan Potassium | Losartan Potassium | 111 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 30 |
| Olanzapine | Olanzapine | 100 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 25 |
| Tramadol Hcl | Tramadol Hcl | 95 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 25 |
| Synthroid | Levothyroxine Sodium | 83 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 26 |
| Finasteride | Finasteride | 73 | 21 |
| Sertraline Hcl | Sertraline Hcl | 73 | 15 |
| Torsemide | Torsemide | 73 | 24 |
| Memantine Hcl | Memantine Hcl | 71 | 16 |
| Meloxicam | Meloxicam | 70 | 17 |
| Carisoprodol | Carisoprodol | 69 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 21 |
| Jardiance | Empagliflozin | 65 | 23 |
| Pregabalin | Pregabalin | 65 | 13 |
| Amoxicillin | Amoxicillin | 64 | 56 |
| Cefdinir | Cefdinir | 63 | 47 |
| Meclizine Hcl | Meclizine Hcl | 63 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 20 |
| Famotidine | Famotidine | 62 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 16 |
| Ibuprofen | Ibuprofen | 60 | 13 |
| Mounjaro | Tirzepatide | 59 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 58 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 17 |
| Spironolactone | Spironolactone | 56 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 54 | 25 |
| Benazepril Hcl | Benazepril Hcl | 53 | 16 |
| Buspirone Hcl | Buspirone Hcl | 53 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 51 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 17 |
| Xarelto | Rivaroxaban | 47 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Trazodone Hcl | Trazodone Hcl | 44 | 12 |
| Donepezil Hcl | Donepezil Hcl | 43 | 14 |
| Januvia | Sitagliptin Phosphate | 43 | 14 |
| Azithromycin | Azithromycin | 42 | 41 |
| Fenofibrate | Fenofibrate,micronized | 42 | 14 |
| Levetiracetam | Levetiracetam | 42 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 40 | 16 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 11 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 30 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | 12 |
| Valsartan | Valsartan | 30 | suppressed |
| Folic Acid | Folic Acid | 28 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Trandolapril | Trandolapril | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Matzim La | Diltiazem Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $715.53 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, GARDASIL 9, JARDIANCE, NURTEC ODT, Ozempic, PROQUAD, SHINGRIX, VAXELIS, VAXNEUVANCE, VENASEAL, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error